Airnov announced on Feb. 5, 2020 at Pharmapack in Paris, France, that it will move forward as an independent company focused on desiccant and oxygen scavenging products for the pharmaceutical, diagnostic, and nutraceutical markets.
Airnov, a healthcare packaging company formerly owned by Clariant, announced on Feb. 5, 2020 at Pharmapack in Paris, France, that it will move forward as an independent company focused on desiccant and oxygen scavenging products for the pharmaceutical, diagnostic, and nutraceutical markets.
As part of its new branding strategy, the company is currently developing environmentally friendly packaging solutions using advanced desiccant polymer (ADP) technology, a desiccant that is integrated directly in the polymer matrix for moisture management, a company press release said. At Pharmapack, the company focused on two commercial launches that used ADP technology, the ADP plate for nutraceutical powder and medical device protection, and the HAT-IN vial with an ADP layer for test strips protection.
"Airnov's newly gained independence and subsequent shorter in-company decision-making lines will make us more flexible and better able to meet customer needs in terms of technical support, product innovation and new developments,” said Dr. Matthias Brommer, president and managing director, Airnov. “Our focus will be on delivering exceptional service, innovation and sustainability, as we rededicate some of the time and attention previously required for corporate processes to help us better focus on fulfilling customer requirements and expectations."
“Our goal is to significantly expand above and beyond current pharmaceutical packaging market growth rates, with new investments, products and technologies, both organically and by acquisition. We continue to look for and evaluate relevant opportunities,” Brommer added in the press release.
Source: Airnov
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.